These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20970601)

  • 1. Genetic polymorphisms and individualized tacrolimus dosing.
    López-Montenegro Soria MA; Kanter Berga J; Beltrán Catalán S; Milara Payá J; Pallardó Mateu LM; Jiménez Torres NV
    Transplant Proc; 2010 Oct; 42(8):3031-3. PubMed ID: 20970601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic factors for individual administration of immunosuppressants in organ transplantation.
    Yu SF; Wu LH; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):337-44. PubMed ID: 16911928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
    Kuypers DR
    Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
    Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients.
    Kuypers DR; de Jonge H; Naesens M; Vanrenterghem Y
    Clin Ther; 2010 Nov; 32(12):2012-23. PubMed ID: 21118736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
    Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
    Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward personalized medicine in renal transplantation.
    Lampreabe I; Gainza de los Rios FJ; Arrieta Gutiérrez A; Jofre-Monseny L; Rodriguez M; Amenabar Iribar JJ; Zárraga Larrondo S; Tejedor D; Martinez A; Olano-Martin E
    Transplant Proc; 2010 Oct; 42(8):2864-7. PubMed ID: 20970553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
    Wang J
    Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
    Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
    J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation.
    Chakkera HA; Chang YH; Bodner JK; Behmen S; Heilman RL; Reddy KS; Mulligan DC; Moss AA; Khamash H; Katariya N; Hewitt WR; Pitta TL; Frassetto LA
    Transplant Proc; 2013; 45(1):137-41. PubMed ID: 23375287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
    Masuda S; Inui K
    Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation.
    Herrero MJ; Sánchez-Plumed J; Galiana M; Bea S; Marqués MR; Aliño SF
    Transplant Proc; 2010 Oct; 42(8):3134-6. PubMed ID: 20970628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
    Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
    Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.
    Wang J; Zeevi A; McCurry K; Schuetz E; Zheng H; Iacono A; McDade K; Zaldonis D; Webber S; Watanabe RM; Burckart GJ
    Transpl Immunol; 2006 Jan; 15(3):235-40. PubMed ID: 16431292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.